Cervical Cancer Deaths Fall to Zero Among Young Women in Historic Vaccine Success
A landmark study reveals that the HPV vaccine has virtually eliminated cervical cancer mortality for women in their early twenties, marking a major triumph for public health.
By Factlen Editorial Team
- Public Health Researchers
- Focus on the unprecedented success of the 2008 vaccine rollout and the concrete mortality data proving its efficacy.
- Cancer Charities
- Celebrate the lives saved while urgently warning that post-pandemic drops in vaccination rates could reverse this progress.
- Medical Practitioners
- Emphasize the biological mechanism of the vaccine, the importance of vaccinating boys, and the ongoing need for adult cervical screening.
What's not represented
- · Parents navigating vaccine hesitancy
- · Adult women diagnosed with cervical cancer prior to the vaccine's rollout
Why this matters
This milestone proves that a targeted vaccination campaign can effectively eradicate a major form of cancer in a single generation. It offers a definitive blueprint for global public health and provides immense reassurance to millions of vaccinated young adults.
Key points
- For the first time, zero cervical cancer deaths were recorded among women aged 20 to 24 in England between 2020 and 2024.
- A major study confirms the HPV vaccine has cut the risk of dying from the disease before age 30 to almost zero.
- The vaccine has already saved an estimated 200 lives, with thousands more expected as the vaccinated cohort ages.
- Health officials warn that recent drops in vaccination rates below the WHO's 90% target could threaten future progress.
- Routine cervical screening remains essential for adults, as the vaccine does not protect against every strain of the virus.
For the first time in recorded medical history, an entire demographic of young women has experienced zero deaths from a disease that was once a leading cause of cancer mortality. Between 2020 and 2024, not a single woman aged 20 to 24 in England died from cervical cancer.[1][2][3]
This extraordinary milestone is the direct result of the human papillomavirus (HPV) vaccination program, which was first introduced in UK schools in 2008. A landmark study published in The Lancet and led by Queen Mary University of London (QMUL) has now quantified the life-saving impact of that rollout, confirming what oncologists had long hoped to see.[1][3]
According to the researchers, women who received the HPV vaccine in early adolescence now face a "virtually zero" risk of dying from cervical cancer before the age of 30. The data provides the strongest national evidence to date that prophylactic vaccination can stop a major cancer in its tracks.[2][3][4]
To understand the magnitude of this achievement, it is necessary to look at how cervical cancer develops. The disease is overwhelmingly caused by high-risk strains of HPV, an extremely common virus that most sexually active adults will encounter at some point in their lives.[2][4]
In most cases, the human immune system clears an HPV infection naturally without causing any symptoms. However, certain high-risk strains can persist in the body for years, gradually causing abnormal cellular changes in the cervix. If left undetected and untreated, these cellular mutations can slowly progress into invasive cervical cancer.[4]
The HPV vaccine works by interrupting this chain of events before it can even begin. Administered to children around the age of 12 or 13—ideally before they become sexually active and are exposed to the virus—the vaccine prompts the immune system to build robust defenses against the most dangerous cancer-causing strains.[2][6]
The HPV vaccine works by interrupting this chain of events before it can even begin.
The results of this biological blockade are now visible in national mortality statistics. The QMUL study, funded by Cancer Research UK, found that even before deaths dropped to absolute zero in the 2020–2024 window, there was already an 80% reduction in cervical cancer deaths among women aged 20 to 24 between 2015 and 2019.[3][6]
Professor Peter Sasieni, the lead author of the study, noted that the vaccine has already prevented an estimated 200 young women from dying of the disease in England alone. Without the vaccine, statistical models suggest that roughly 23 deaths would have been expected in the 20-to-24 age bracket over the last five years.[1][2][4]
As the first generation of vaccinated girls grows older, the number of lives saved is projected to skyrocket. Cervical cancer risk typically peaks when women reach their 30s and 40s. Because the vaccine provides long-lasting, potentially lifelong protection, epidemiologists expect to see thousands of deaths prevented in the coming decades.[2][3]
The success of the program has also led to its expansion. In 2019, the UK began offering the HPV vaccine to boys as well. This dual-gender approach not only helps establish herd immunity by reducing the overall circulation of the virus, but it also protects young men from HPV-related head, neck, and genital cancers.[6]
Despite the overwhelming clinical triumph, public health officials are warning against complacency. The World Health Organization (WHO) has set a global target of 90% vaccination coverage to fully eliminate cervical cancer. While the UK previously hovered near this benchmark, uptake has slipped in the wake of the COVID-19 pandemic.[2][6]
Recent data shows that in England, nearly 72% of girls and 67% of boys were vaccinated in Year 8 during the 2024–2025 academic year. Cancer Research UK has expressed concern that roughly one in four young people are currently leaving school unprotected, warning that falling vaccination rates could lead to a resurgence of avoidable deaths.[5][6]
Medical experts also stress that the vaccine does not eliminate the need for routine cervical screening, commonly known as smear tests. Because the current vaccines protect against the majority of high-risk HPV strains but not all of them, women aged 25 to 64 are still strongly advised to attend their screening appointments to catch any abnormal cells early.[2][4]
How we got here
2008
The UK introduces a national school-based HPV vaccination program for girls aged 12 to 13.
2015–2019
Cervical cancer mortality among women aged 20 to 24 drops by 80% compared to pre-vaccine levels.
2019
The HPV vaccination program is officially expanded to include school-aged boys.
2020–2024
England records zero cervical cancer deaths among women aged 20 to 24 for the first time in history.
June 2026
The Lancet publishes landmark data confirming the near-total elimination of early-onset cervical cancer mortality.
Viewpoints in depth
Public Health Researchers
Scientists emphasize the unprecedented success of the 2008 rollout in eliminating a major cancer.
For epidemiologists and oncologists, the data published in The Lancet represents a generational victory. Researchers at Queen Mary University of London point out that it is exceedingly rare to see a public health intervention completely eradicate mortality for a specific disease demographic within two decades. They argue that the zero-death milestone proves the biological efficacy of the HPV vaccine beyond any doubt, validating the massive logistical effort required to launch the school-based immunization program in 2008.
Cancer Charities
Advocates celebrate the milestone but warn that falling vaccination rates threaten future generations.
Organizations like Cancer Research UK view the findings as a powerful testament to what science can achieve, but they are simultaneously sounding the alarm on recent trends. With current vaccination rates for Year 8 girls hovering around 72%—well below the World Health Organization's 90% target—charities warn that the pandemic has disrupted routine immunizations. They argue that without immediate catch-up campaigns and renewed public education, the UK risks seeing a tragic and entirely avoidable resurgence of cervical cancer cases in the future.
Medical Practitioners
Clinicians focus on the need for continued screening and the broader benefits of vaccinating boys.
Frontline doctors and gynecologists stress that while the vaccine is a medical marvel, it is not a silver bullet that ends all cervical care. Because the jab targets the most aggressive cancer-causing strains of HPV but does not cover every variant, practitioners emphasize that adult women must still attend routine smear tests. Furthermore, clinicians advocate strongly for the continued vaccination of boys, noting that it not only protects women through herd immunity but also prevents a rising tide of HPV-related throat and neck cancers in men.
What we don't know
- Whether the recent post-pandemic dip in vaccination rates will lead to a measurable spike in cervical cancer cases in the coming decade.
- Exactly how long the vaccine's protection lasts into late adulthood, though current data suggests it may be lifelong.
Key terms
- Human Papillomavirus (HPV)
- A very common group of viruses, certain high-risk strains of which can cause cellular changes that lead to cervical and other cancers.
- Prophylactic Vaccine
- A vaccine administered to prevent a disease from occurring, rather than treating it after an infection has taken hold.
- Cervical Screening
- A routine medical test (often called a smear test) that checks the health of the cervix to detect early abnormal cell changes before they turn into cancer.
- Herd Immunity
- When a high enough percentage of a population is vaccinated against a disease, making its spread from person to person unlikely, which protects those who are unvaccinated.
Frequently asked
Does the HPV vaccine mean I no longer need smear tests?
No. While the vaccine protects against the most common cancer-causing strains of HPV, it does not cover every single strain. Women aged 25 to 64 are still advised to attend routine cervical screenings.
Why are boys now given the HPV vaccine?
Vaccinating boys helps create herd immunity by reducing the overall spread of the virus. It also directly protects men against HPV-related head, neck, and genital cancers.
Is it too late to get the vaccine if I missed it in school?
In many countries, including the UK, individuals who missed their school vaccination can still receive the HPV jab for free via their doctor up to the age of 25. Older adults can also access it privately.
Sources
Source coverage
6 outlets
3 viewpoints surfaced
[1]BBCCancer Charities
Cervical cancer deaths fall to zero in young women given vaccine
Read on BBC →[2]The GuardianCancer Charities
HPV jabs cut risk of dying from cervical cancer before 30 to almost zero
Read on The Guardian →[3]Queen Mary University of LondonPublic Health Researchers
First of its kind research shows HPV vaccine reducing cervical cancer deaths
Read on Queen Mary University of London →[4]CosmopolitanMedical Practitioners
Women vaccinated against HPV as teenagers have a 'close to zero' risk of dying from cervical cancer
Read on Cosmopolitan →[5]Patient Safety LearningMedical Practitioners
Cervical cancer deaths in young women fall to zero for first time after vaccine introduced
Read on Patient Safety Learning →[6]Mansfield 103.2
Children vaccinated for HPV have close to zero risk of dying from cervical cancer before age 30, study suggests
Read on Mansfield 103.2 →
Every angle. Every day.
Get health stories with full source coverage and perspective breakdowns delivered to your inbox.